

# David W Haas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5178265/publications.pdf>

Version: 2024-02-01

72  
papers

5,580  
citations

218677

26  
h-index

88630

70  
g-index

78  
all docs

78  
docs citations

78  
times ranked

12480  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Clinical Prediction Model for Unsuccessful Pulmonary Tuberculosis Treatment Outcomes. <i>Clinical Infectious Diseases</i> , 2022, 74, 973-982.	5.8	9
2	Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. <i>Pharmacogenetics and Genomics</i> , 2022, 32, 24-30.	1.5	3
3	Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa. <i>Journal of Infectious Diseases</i> , 2022, 226, 147-156.	4.0	8
4	Pharmacogenetics of Dolutegravir Plasma Exposure Among Southern Africans With Human Immunodeficiency Virus. <i>Journal of Infectious Diseases</i> , 2022, 226, 1616-1625.	4.0	3
5	Efavirenz Pharmacogenetics and Weight Gain Following Switch to Integrase Inhibitor-Containing Regimens. <i>Clinical Infectious Diseases</i> , 2021, 73, e2153-e2163.	5.8	32
6	IFNL4 Genotype Does Not Associate with CD4 T-Cell Recovery in People Living with Human Immunodeficiency Virus. <i>AIDS Research and Human Retroviruses</i> , 2021, 37, 184-188.	1.1	2
7	Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens. <i>Clinical Infectious Diseases</i> , 2021, 72, 1820-1822.	5.8	4
8	Pharmacokinetics and Drug-Drug Interactions of Isoniazid and Efavirenz in Pregnant Women Living With HIV in High TB Incidence Settings: Importance of Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 1034-1044.	4.7	20
9	Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir- and Tenofovir-containing Regimens. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, Publish Ahead of Print, 1002-1009.	2.1	6
10	Pharmacogenetics of tenofovir and emtricitabine penetration into cerebrospinal fluid. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1206.	0.9	2
11	Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults. <i>PLoS Genetics</i> , 2021, 17, e1009464.	3.5	11
12	Transdisciplinary Perspectives on Precision Medicine. <i>Health Equity</i> , 2021, 5, 288-298.	1.9	1
13	Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine. <i>Pharmacogenetics and Genomics</i> , 2021, 31, 17-27.	1.5	10
14	Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy. <i>Aids</i> , 2021, 35, 439-445.	2.2	11
15	A high-resolution HLA reference panel capturing global population diversity enables multi-ancestry fine-mapping in HIV host response. <i>Nature Genetics</i> , 2021, 53, 1504-1516.	21.4	69
16	Mitochondrial DNA Haplogroups and Frailty in Adults Living with HIV. <i>AIDS Research and Human Retroviruses</i> , 2020, 36, 214-219.	1.1	6
17	Effects of Pregnancy and Isoniazid Preventive Therapy on Mycobacterium tuberculosis Interferon Gamma Response Assays in Women With HIV. <i>Clinical Infectious Diseases</i> , 2020, 73, e3555-e3562.	5.8	9
18	HLA tapasin independence: broader peptide repertoire and HIV control. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 28232-28238.	7.1	51

#	ARTICLE	IF	CITATIONS
19	Endogenous Retroviral Envelope Syncytin Induces HIV-1 Spreading and Establishes HIV Reservoirs in Placenta. <i>Cell Reports</i> , 2020, 30, 4528-4539.e4.	6.4	25
20	Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives. <i>Pharmacogenetics and Genomics</i> , 2020, 30, 45-53.	1.5	9
21	CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome. <i>Nature Immunology</i> , 2019, 20, 824-834.	14.5	87
22	GCH1 haplotypes and cardiovascular risk in HIV. <i>Aids</i> , 2019, 33, 1669-1671.	2.2	1
23	Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naïve Clinical Trial. <i>Clinical Infectious Diseases</i> , 2019, 68, 1044-1047.	5.8	22
24	Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 699-709.	3.0	13
25	ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)â€™infected Participants With HIV-1 RNA <math>\leq 500000</math> Copies/mL. <i>Clinical Infectious Diseases</i> , 2018, 66, 1689-1697.	5.8	83
26	Elevated <i>HLA-A</i> expression impairs HIV control through inhibition of NKG2A-expressing cells. <i>Science</i> , 2018, 359, 86-90.	12.6	135
27	Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e64-e75.	9.1	119
28	Precision HIV care: responding to old questions and meeting new challenges. <i>Pharmacogenomics</i> , 2018, 19, 1299-1302.	1.3	1
29	Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events. <i>Pharmacogenetics and Genomics</i> , 2018, 28, 179-187.	1.5	4
30	Hemochromatosis (<i>HFE</i>) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 2018, 34, 942-949.	1.1	4
31	Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2460-2467.	3.0	17
32	Killer cell immunoglobulinâ€™like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. <i>Journal of Clinical Investigation</i> , 2018, 128, 1903-1912.	8.2	52
33	Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	3
34	Evaluating the Impact of Functional Genetic Variation on HIV-1 Control. <i>Journal of Infectious Diseases</i> , 2017, 216, 1063-1069.	4.0	20
35	HLA-B*14:02-Restricted Env-Specific CD8 + T-Cell Activity Has Highly Potent Antiviral Efficacy Associated with Immune Control of HIV Infection. <i>Journal of Virology</i> , 2017, 91, .	3.4	14
36	Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles. <i>Scientific Reports</i> , 2017, 7, 8653.	3.3	41

#	ARTICLE	IF	CITATIONS
37	Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants. <i>Journal of Infectious Diseases</i> , 2017, 216, 554-564.	4.0	23
38	Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens. <i>Open Forum Infectious Diseases</i> , 2017, 4, S433-S433.	0.9	1
39	Patient willingness to undergo efavirenz dose reduction based on pharmacogenetic testing. <i>Personalized Medicine</i> , 2016, 13, 241-247.	1.5	0
40	Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342). <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1609-1618.	3.0	11
41	Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 146-156.	2.4	64
42	Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202. <i>Pharmacogenetics and Genomics</i> , 2015, 25, 450-461.	1.5	15
43	Combined Effect of CYP2B6 and NAT2 Genotype on Plasma Efavirenz Exposure During Rifampin-based Antituberculosis Therapy in the STRIDE Study. <i>Clinical Infectious Diseases</i> , 2015, 60, 1860-1863.	5.8	28
44	Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv085.	0.9	19
45	Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 14658-14663.	7.1	154
46	Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofu113.	0.9	37
47	Novel Dosing Strategies Increase Exposures of the Potent Antituberculosis Drug Rifapentine but Are Poorly Tolerated in Healthy Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 3399-3405.	3.2	11
48	Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice. <i>Pharmacogenomics</i> , 2015, 16, 2007-2018.	1.3	19
49	Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Antituberculosis Drug PA-824 with Concomitant Lopinavir-Ritonavir, Efavirenz, or Rifampin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 5245-5252.	3.2	42
50	Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2187-2190.	3.0	18
51	Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2175-2182.	3.0	49
52	Defining the role of common variation in the genomic and biological architecture of adult human height. <i>Nature Genetics</i> , 2014, 46, 1173-1186.	21.4	1,818
53	Genetic and Non-Genetic Determinants of Raltegravir Penetration into Cerebrospinal Fluid: A Single Arm Pharmacokinetic Study. <i>PLoS ONE</i> , 2013, 8, e82672.	2.5	10
54	Clinical perspectives on human genetic screening to prevent nevirapine toxicity. <i>Personalized Medicine</i> , 2012, 9, 773-782.	1.5	4

#	ARTICLE	IF	CITATIONS
55	The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation. <i>Science</i> , 2010, 330, 1551-1557.	12.6	1,054
56	Hepatotoxicity and Gastrointestinal Intolerance When Healthy Volunteers Taking Rifampin Add Twice-Daily Atazanavir and Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 50, 290-293.	2.1	87
57	A Randomized Study of Antiviral Medication Switch at Lower-Versus Higher-Switch Thresholds: AIDS Clinical Trials Group Study A5115. <i>Antiviral Therapy</i> , 2007, 12, 531-541.	1.0	18
58	Can Responses to Antiretroviral Therapy Be Improved by Therapeutic Drug Monitoring?. <i>Clinical Infectious Diseases</i> , 2006, 42, 1197-1199.	5.8	6
59	Pharmacogenetics of Nevirapine-Associated Hepatotoxicity: An Adult AIDS Clinical Trials Group Collaboration. <i>Clinical Infectious Diseases</i> , 2006, 43, 783-786.	5.8	131
60	Pharmacogenetics of Long-Term Responses to Antiretroviral Regimens Containing Efavirenz and/or Nelfinavir: An Adult AIDS Clinical Trials Group Study. <i>Journal of Infectious Diseases</i> , 2005, 192, 1931-1942.	4.0	232
61	Pharmacogenomics of antiretroviral therapy. <i>Drug Development Research</i> , 2004, 62, 213-220.	2.9	4
62	Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. <i>Aids</i> , 2004, 18, 2391-400.	2.2	429
63	Effects of Ritonavir on Indinavir Pharmacokinetics in Cerebrospinal Fluid and Plasma. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 2131-2137.	3.2	43
64	MDR1 Gene Polymorphisms and Phase 1 Viral Decay During HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 34, 295-298.	2.1	54
65	Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial. <i>Aids</i> , 2003, 17, 1339-1349.	2.2	81
66	A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128. <i>HIV Clinical Trials</i> , 2003, 4, 287-300.	2.0	66
67	Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 68, 367-374.	4.7	41
68	Factors That Predict Incomplete Virological Response to Protease Inhibitor-Based Antiretroviral Therapy. <i>Clinical Infectious Diseases</i> , 1999, 29, 75-81.	5.8	36
69	No influence of large volume blood loss on serum vancomycin concentrations during orthopedic procedures. <i>Acta Orthopaedica</i> , 1999, 70, 47-50.	1.4	7
70	Tuberculous Pericarditis in an HIV-Infected Patient. <i>Scandinavian Journal of Infectious Diseases</i> , 1995, 27, 411-413.	1.5	5
71	Marked Polymorphonuclear Pleocytosis Due to Blastomycotic Meningitis: Case Report and Review. <i>Clinical Infectious Diseases</i> , 1994, 18, 816-818.	5.8	24
72	Antimicrobial Prophylaxis of Infections Associated with Foreign Bodies. , 0, , 395-406.		7